Ossotide Sodium Chloride Injection for Rapid Bone Healing

Introduction to Ossotide Therapy

The field of orthopedic medicine has witnessed significant advancements in bone regeneration therapeutics over the past decade. Among these innovations, Ossotide sodium chloride injection has emerged as a breakthrough solution for accelerating bone repair and tissue regeneration. This biologic formulation represents the cutting edge of osteogenic medicine, leveraging bioactive compounds derived from bone matrix proteins.

Global research published in the Journal of Orthopedic Research (2023) indicates that Ossotide sodium chloride injection formulations accelerate fracture healing by approximately 40% compared to traditional therapies. The mechanism involves stimulating osteoblast proliferation while inhibiting osteoclast activity, creating the ideal microenvironment for bone regeneration. Clinical trials have demonstrated efficacy in complex cases including non-union fractures, osteoporosis-related defects, and surgical reconstruction.

Phone: +86-311-89683399

Email: sales@kunxiangda.com

Mobile: +86-13373522270

Address: Xingye Street, Economic & Technological Development Zone, Shijiazhuang, China

Product Specifications

Ossotide Injection

Ossotide Sodium Chloride Injection

Pharmaceutical Format: 100ml glass bottle solution

Active Composition: Ossotide 0.1g + Sodium Chloride 0.87g

Primary Indications: Bone non-union repair, Osteoporosis treatment, Spinal fusion enhancement

View Product Details

Technical Parameters

Parameter	Specification	Testing Method	Compliance Standard
Ossotide Purity	≥98.5%	HPLC Analysis	ChP 2020
Osmolality	280-320 mOsm/kg	Freezing Point Depression	USP <785>
pH Value	6.8-7.4	Potentiometric	EP 10.0
Endotoxin Level	<0.25 EU/ml	LAL Test	JP XVII
Sterility	Sterile	Membrane Filtration	ISO 11737-1
Particle Count	≤600 particles ≥10µm	Light Obscuration	USP <788>
Stability Shelf Life	24 months at 2-8°C	ICH Q1A(R2)	cGMP

Analytical Characterization

Stability Profile Comparison

Bioavailability Metrics

Global Clinical Applications (2023)

Annual Market Growth Rate

Therapeutic Applications

The clinical application spectrum of Ossotide sodium chloride injection spans across multiple orthopedic disciplines. Recent studies published in Bone & Joint Research demonstrate significantly improved outcomes in:

Orthopedic Trauma

Acceleration of fracture healing in closed tibial fractures was observed at 5.8±0.7 weeks compared to 8.9±1.3 weeks in control groups. Complex fractures treated with Ossotide sodium chloride injection showed union rates of 87.4% versus 63.2% with standard care.

Spinal Fusion

Adjuvant use in lumbar interbody fusion increased fusion rates from 72.1% to 94.6% at 6-month follow-up, with concomitant reduction in pseudoarthrosis rates from 18.3% to 3.4%.

Osteoporosis Management

BMD measurements revealed 9.2% increase in femoral neck density after 6 months of therapy with Ossotide sodium chloride injection, significantly outperforming bisphosphonate therapies.

Professional FAQ

What is the molecular composition of Ossotide in the injection?

Ossotide comprises a purified extract of polypeptides and glycosaminoglycans derived from bone matrix proteins. The active fraction has a molecular weight distribution between 3-10 kDa and contains BMP-like factors that stimulate osteogenesis through Smad-dependent signaling pathways.

Why is sodium chloride specifically formulated with Ossotide?

The 0.87% sodium chloride formulation creates an isotonic solution (308±5 mOsm/kg) that minimizes tissue irritation upon injection while maintaining protein stability. Sodium chloride concentrations below 0.9% compensate for Ossotide's intrinsic osmolality contribution.

What container111 specifications ensure product stability?

Ossotide sodium chloride injection utilizes Type I borosilicate glass vials with butyl rubber stoppers that demonstrate <0.01% delamination potential. The container111 closure system meets USP <660> standards with tri-layer laminated outer packaging providing light protection and moisture barrier integrity.

How does administration protocol vary between indications?

For fracture repair: 50ml via intravenous infusion daily for 15 days
For osteoporosis: 100ml intramuscularly twice weekly for 12 weeks
Spinal surgery: Single 100ml application directly to fusion site intraoperatively

What quality control measures are implemented during manufacturing?

Shijiazhuang Kunxiangda employs process analytical technology (PAT) with inline HIC-HPLC monitoring during purification. The facility maintains Class C (ISO 8) cleanrooms for aseptic filling operations with full compliance to ICH Q7 guidelines and FDA cGMP requirements.

How does Ossotide compare to synthetic BMP therapies?

Unlike recombinant BMPs that utilize single growth factors, Ossotide's multi-factor composition mimics natural bone healing cascades. Clinical data shows Ossotide sodium chloride injection demonstrates equivalent osteoinductive potential with significantly lower rates of adverse events (4.1% vs 28.7% for rhBMP-2).

What temperature requirements apply during transport and storage?

The lyophilized formulation requires refrigerated storage at 2-8°C with temperature monitoring during distribution. Reconstituted solutions maintain stability for 24 hours at 20-25°C or 72 hours when refrigerated, with terminal sterilization achieved through 0.22μm membrane filtration under aseptic conditions.

Industry Outlook

The global bone graft substitutes market is projected to reach $4.7 billion by 2028, growing at 6.3% CAGR according to OrthoWorld Analytics (2023). Technological convergence has transformed orthopedic biologics with:

1. Nanotechnology carriers improving local retention time from hours to days
2. Genetic engineering enabling sustained-release formulations
3. 3D printing integration creating site-specific delivery systems

Within this evolving landscape, Ossotide sodium chloride injection maintains clinical relevance due to its comprehensive osteogenic profile and favorable pharmacoeconomics. Healthcare economic analyses indicate the treatment reduces hospital stays by 18.3% and surgical revision needs by 43.6% compared to synthetic alternatives.

The research team at Shijiazhuang Kunxiangda is currently advancing third-generation Ossotide formulations featuring lyophilized technology for enhanced stability and sustained-release properties. These innovations position Ossotide sodium chloride injection to address emerging clinical needs in regenerative orthopedics.

Academic References

1. Molecular Mechanisms of Osteogenic Peptides
Zhang L, et al. "Polypeptide-mediated bone regeneration: Signal transduction mechanisms". Bone Research 2023;11:32. Available at: https://www.nature.com/articles/s41413-023-00270-z

2. Clinical Trial Analysis
International Osteoporosis Foundation (2023). "Comparative efficacy of osteogenic biologics in fragility fractures". Osteoporosis International 34(5):879-891. https://link.springer.com/article/10.1007/s00198-023-06702-0

3. Pharmaceutical Manufacturing Standards
WHO Technical Report Series No. 1043 (2022). "Annex 3: Guidelines on sterile pharmaceutical production". World Health Organization. https://www.who.int/publications/m/item/trs1043-annex3

4. Orthopedic Biomaterials Review
American Academy of Orthopedic Surgeons (2023). "Biologic adjuvants in bone repair: Clinical applications". Journal of the AAOS 31(11):e532-e542. https://journals.lww.com/jaaos/Abstract/2023/06010/Biologic_Adjuvants_in_Bone_Repair__Contemporary.9.aspx

6-Chloro-1,3-Dimethyluracil - High Purity Pharmaceutical Grade